Marco Stief – författare

This commentary offers the definitive guide to supplementary protection certificates (SPC); a key element in the regulation of the pharmaceutical and medical market within Europe. Beyond providing an overview of the European legislation and the CJEU case-law on SPCs, it also depicts and summarises national law and jurisprudence on leading pharmaceutical markets such as Germany, France and the United Kingdom as well as The Netherlands, Italy and Switzerland. Patent lawyers, those practising in the medical and pharmaceutical field as well as judges and academics will find this an invaluable resource.

This handbook focuses on German jurisprudence to identify key principles and trends, thereby providing valuable assistance and arguments in other jurisdictions.Germany is one of the world’s leading jurisdictions for patent litigation. In Europe alone, approximately 60% of patent disputes are heard before courts in Germany. Answers to key questions in patent law and the possible interpretation thereof may be found in case law from German courts. Pharmaceutical, biological and chemical patents are key matters in patent law. The fields present multiple challenges and legal disputes, especially in relation to matters of ‘state of the art’ and the different identifications of a substance and the resulting patents. German courts have given valuable insights to resolving globally significant issues.